The company targets key fibrotic mediator proteins that aid in the development of fibrosis in chronically-damaged organs, and has developed antibody-based therapeutics that enable medical practitioners to halt and reverse critical fibrosis and associated conditions. Mediar is pioneering a new approach to fibrosis treatment that halts the disease at a different source, and combines novel targets with reliable, easily detectable blood biomarkers and familiar modalities to derisk the path forward for fibrosis therapies in clinical development.